Allos' PDX Yields Positive Interim Data in PTCL Trial

As the industry prepared for the first deluge of American Society of Clinical Oncology (ASCO) data Thursday night, cancer drug company Allos Therapeutics Inc. managed to capture a little attention of its own early in the day by reporting promising interim data from its pivotal Phase II study of PDX (pralatrexate) in peripheral T-cell lymphoma (PTCL). (BioWorld Today)